Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Julie Dubourg"'
Autor:
Valentina Forni Ogna, Anne Blanchard, Rosa Vargas-Poussou, Adam Ogna, Stéphanie Baron, Jean-Philippe Bertocchio, Caroline Prot-Bertoye, Jérôme Nevoux, Julie Dubourg, Gérard Maruani, Margarida Mendes, Alejandro Garcia-Castaño, Cyrielle Treard, Nelly Lepottier, Pascal Houillier, Marie Courbebaisse
Publikováno v:
PLoS ONE, Vol 12, Iss 5, p e0177329 (2017)
BACKGROUND AND OBJECTIVES:Hypocitraturia has been associated with metabolic acidosis and mineral disorders. The aim of this study was to investigate the occurrence of urinary acidification defects underlying hypocitraturia. MATERIALS AND METHODS:This
Externí odkaz:
https://doaj.org/article/c07388da92ac41fdb4947c4ddf2f7a24
Autor:
Stephen A. Harrison, Carole Thang, Sébastien Bolze, Sheila Dewitt, Sophie Hallakou-Bozec, Julie Dubourg, Pierre Bedossa, Kenneth Cusi, Vlad Ratziu, Jean-Marie Grouin, David E. Moller, Pascale Fouqueray
Publikováno v:
Journal of Hepatology. 78:914-925
Publikováno v:
Nature Medicine. 29:562-573
Publikováno v:
Clinical Gastroenterology and Hepatology.
Publikováno v:
Diabetes, Obesity and Metabolism. 24:609-619
To evaluate the safety and efficacy of imeglimin for 52 weeks as monotherapy or combination therapy with existing antidiabetic agents in Japanese patients with type 2 diabetes.TIMES 2 was a phase 3, pivotal, open-label trial including patients with t
Autor:
Julie Dubourg, David E. Moller, Sébastien Bolze, Jean-Marie Grouin, Naim Alkhouri, Sophie Hallakou-Bozec, Pascale Fouqueray, Stephen A. Harrison, Vlad Ratziu, Kenneth Cusi, S. Megnien
Publikováno v:
The Lancet Gastroenterology & Hepatology. 6:889-902
Summary Background AMP kinase (AMPK) is an energy sensor implicated in regulation of lipid metabolism, inflammation, and insulin sensitivity. We aimed to assess efficacy and safety of PXL770, a novel direct AMPK activator, in patients with non-alcoho
Publikováno v:
Diabetes, Obesity & Metabolism
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, 23 (3), pp.800-810. ⟨10.1111/dom.14285⟩
Diabetes, Obesity and Metabolism
Diabetes, Obesity and Metabolism, Wiley, 2021, 23 (3), pp.800-810. ⟨10.1111/dom.14285⟩
International audience; AIMS: The aim of this study was to assess the efficacy and safety of imeglimin monotherapy compared to placebo for 24 weeks in Japanese patients with type 2 diabetes mellitus (T2DM).MATERIAL AND METHODS: In this 24-week, rando
Publikováno v:
Clinical Pharmacokinetics. 60:485-490
Imeglimin is a novel oral antidiabetic drug used to treat type 2 diabetes, targeting the mitochondrial bioenergetics. Imeglimin is mainly excreted unchanged by the kidneys and is a substrate of organic cation transporters, which are expressed in the
Autor:
Sandrine Perrimond-Dauchy, Pascal Voiriot, Mathieu Felices, Sébastien Bolze, Julie Dubourg, Pascale Fouqueray
Publikováno v:
European Journal of Clinical Pharmacology. 76:1393-1400
Imeglimin is the first in a new class of oral antidiabetic agents, the glimins, currently in development to improve glycemic control in patients with type 2 diabetes mellitus. A thorough QT study was conducted to establish electrophysiological effect
Autor:
null Caroline Reilhac, null Julie Dubourg, null Carole Thang, null Jean‐Marie Grouin, null Pascale Fouqueray, null Hirotaka Watada
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69130d4a90f9dc09dfda4fb2e4df51ec
https://doi.org/10.1111/dom.14642/v2/response1
https://doi.org/10.1111/dom.14642/v2/response1